Search

Search results

13478 results found

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Strober, Bruce, Melinda Gooderham, Elke M G J de Jong, Alexa B Kimball, Richard G Langley, Nikita Lakdawala, Kavitha Goyal, et al. 2018. “Depressive Symptoms, Depression, and the Effect of Biologic Therapy Among Patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR).”. Journal of the American Academy of Dermatology 78 (1): 70-80.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies.

Reich, K, K A Papp, A W Armstrong, Y Wasfi, S Li, Y K Shen, B Randazzo, M Song, and A B Kimball. 2019. “Safety of Guselkumab in Patients With Moderate-to-Severe Psoriasis Treated through 100 Weeks: A Pooled Analysis from the Randomized VOYAGE 1 and VOYAGE 2 Studies.”. The British Journal of Dermatology 180 (5): 1039-49.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.

Langley, R G, A B Kimball, H Nak, W Xu, B Pangallo, O O Osuntokun, N Agada, and K Reich. 2019. “Long-Term Safety Profile of Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis from 11 Clinical Trials.”. Journal of the European Academy of Dermatology and Venereology : JEADV 33 (2): 333-39.